NASDAQ
Alnylam Pharmaceuticals, Inc. (ALNY) has a revenue compound annual growth rate of 49.77% over 5 years and 56.89% over 10 years. Revenue CAGR shows the compound annual growth rate of a company's total sales, indicating the pace of top-line expansion.
No price data available for this timeframe.